Neoadjuvant Pembrolizumab Plus Chemo Treats Early TNBC
Researchers found that at 36 months, the estimated event-free survival was 84.5 and 76.8% in the pembrolizumab-chemotherapy and placebo-chemotherapy groups, respectively.
Source: empr.com
Page 7 - Peter Schmid News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Peter Schmid. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Peter Schmid Today - Breaking & Trending Today
Doctors working on biggest shake-up in breast cancer screening for 30 years
Trials have been launched in a bid to remedy long-running concerns that the system is prone to false alarms and misses cases in some women.
Source: dailymail.co.uk
Immunotherapy Treatment Shows Promise for Triple Negative Breast Cancer
The addition of neoadjuvant pembrolizumab to chemotherapy reduced triple negative breast cancer recurrence by more than a third, trial results suggested.
Source: medscape.com
New drug combination for aggressive breast cancer could save thousands of lives
The trial, named KEYNOTE-522, is the first phase III trial to demonstrate the benefit of adding immunotherapy to chemotherapy before patients receive
Source: miragenews.com
Powerful drug combination for breast cancer 'could save thousands of lives'
Around 15 of all breast cancers (more than 8,000 cases per year in the UK) are triple negative breast cancer.
Source: impartialreporter.com